Traitement des dyslipidémies et atteinte hépatique [Lipid-lowering treatment and liver dysfunction].

Details

Serval ID
serval:BIB_E5B0900672DA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Traitement des dyslipidémies et atteinte hépatique [Lipid-lowering treatment and liver dysfunction].
Journal
Revue Médicale Suisse
Author(s)
Gencer B., Moradpour D., Rodondi N.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2012
Volume
8
Number
331
Pages
507-512
Language
french
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Abstract
Statins are a cornerstone of cardiovascular prevention. Their utilization is mostly well tolerated and safe: the commonly reported hepatic adverse effect is an asymptomatic, reversible and dose-related increase in liver enzyme levels occurring in case of risks factors. Statins do not worsen liver function in most patients with chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, and might be used cautionsly. However, decompensated cirrhosis and acute liver failure are contraindications for statins. Routine hepatic biochemical test monitoring is questioned and might be performed in following situations: chronic liver diseases, alcohol consumption, drug interactions. Other causes should be screened and treatment be temporarily withheld in case of an ALT elevation > 3 times the upper limit of the norm.
Keywords
Decision Trees, Dyslipidemias/complications, Dyslipidemias/drug therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Liver/drug effects, Liver/physiopathology, Liver Diseases/complications, Liver Function Tests
Pubmed
Create date
31/05/2012 18:37
Last modification date
20/08/2019 16:09
Usage data